About Actemra Actemra may be the result of analysis collaboration by Chugai and has been co-created globally with Chugai. Actemra may be the initial humanized interleukin-6 receptor-inhibiting monoclonal antibody. An extensive clinical development program of five Phase III trials was designed to evaluate clinical findings of Actemra. The five studies have reported meeting their primary endpoints. Actemra is awaiting approval in the usa and Europe. In Japan, Actemra was launched by Chugai in June 2005 as a therapy for Castleman’s disease; in 2008 April, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis had been accepted in Japan also.For allergens with seasonal variation, individuals were tested out of time of year for pollens affecting their asthma; all sufferers had no additional lung disease. All the asthma medications had been discontinued at least 4 weeks before enrollment. Patients were excluded from the study if they acquired worsening of asthma, respiratory-related visits to the emergency section within 6 weeks before study enrollment, previous usage of AMG 157, or known sensitivity to any AMG 157 excipients. Study Design We conducted this proof-of-concept, randomized, double-blind, placebo-controlled study in five centers in Canada. Patients were randomly assigned, in a 1:1 ratio, through an interactive voice-response system to receive 700 mg of AMG 157 or placebo in a 1-hour intravenous infusion on study times 1, 29, and 57.